Drug Patents owned by Acadia Pharms Inc
1. List of Nuplazid drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7923564 | ACADIA PHARMS INC | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms |
Sep, 2025
(2 years from now) | |
| US7732615 | ACADIA PHARMS INC | N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
Jun, 2028
(5 years from now) | |
| US7601740 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Apr, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9765053 | ACADIA PHARMS INC | Methods of treatment using selective 5-HT2A inverse agonists |
Jul, 2022
(7 months ago) | |
| US8921393 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan, 2024
(9 months from now) | |
| US8618130 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan, 2024
(9 months from now) | |
| US9566271 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan, 2024
(9 months from now) | |
| US10028944 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan, 2024
(9 months from now) | |
| US7659285 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Aug, 2026
(3 years from now) | |
| US10953000 | ACADIA PHARMS INC | Combination of pimavanserin and cytochrome P450 modulators |
Mar, 2037
(14 years from now) | |
| US10517860 | ACADIA PHARMS INC | Combination of pimavanserin and cytochrome P450 modulators |
Mar, 2037
(14 years from now) | |
| US10646480 | ACADIA PHARMS INC | Formulations of pimavanserin |
Aug, 2038
(15 years from now) | |
| US10849891 | ACADIA PHARMS INC | Formulations of pimavanserin |
Aug, 2038
(15 years from now) | |
| US10449185 | ACADIA PHARMS INC | Formulations of pimavanserin |
Aug, 2038
(15 years from now) | |
| US11452721 | ACADIA PHARMS INC | Formulations of pimavanserin |
Aug, 2038
(15 years from now) | |
Drugs and Companies using PIMAVANSERIN TARTRATE ingredient
Market Authorisation Date: 29 April, 2016
Treatment: Treatment of hallucinations and delusions associated with parkinson's disease psychosis; Treatment of a neurodegenerative disease or a symptom thereof; Treatment of psychosis or a symptom thereof; Treatment of parkinson's disease psychosis
Dosage: TABLET;ORAL
NUPLAZID family patents
62
United States
10
China
10
European Union
7
Russia
7
Japan
6
Canada
6
Australia
5
Spain
5
Korea, Republic of
5
South Africa
5
Denmark
4
Mexico
4
Hong Kong
3
Singapore
3
Brazil
3
New Zealand
3
Austria
3
Slovenia
2
Portugal
2
Germany
2
Sweden
2
Cyprus
2
Poland
1
Israel
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic